provide for remainder joining we a business update, the quarter for Good Then results, XXXX second us. will today's provide an the line thank will present afternoon, On outlook and questions. XXXX. open you and call, of for our we financial
was Chairman in welcome to more an I Chuck the leadership veteran Directors. annual Scientific. President that that, experience Chuck quarterly where Lab Fisher years of Mass already. recently, of know than their led $X Most strategic XX would of Board a of Independent He's was Board. to Chuck Bio-Techne, Life joined QSI the billion. to revenue both like he results, than of our and as of Thermo division Sciences. reviewing in probably Many Chuck Consumables of our CEO Spectrometry Kummeth you and drove to more increase Chuck recently industry our President Before initiatives with XXX% Prior
have Platinum, benefiting power We labs over the mover from world. that the of to in advantage the around the our excited are are years.
At that we we forward to in market the to a sequencing capture technology protein believe Quantum-Si, billion positions Chuck first look We next-generation his to us a industry-leading and and well proteomics. share counsel on we to coming committed have research Board, bringing of $XX leading
same in of the Next-generation to way proteomic has way market create next to and transformed the DNA believe tests. will protein research sequencing science opportunities the life for large, new enable much sequencing pave the of that new ultimately new will research. accelerate help discovery therapies biomarkers and We the that diagnostic development generation potential Platinum
on update XXXX. priorities an our Now provide I would corporate like to for
a As deliver strength. commercial XXXX: priorities X our reminder, on accelerate for roadmap; financial third, have corporate first, we preserve and adoption; innovation second,
of Platinum to quarter priority exiting the the full accelerate end at adoption. sales QX launch first commercial the quarter. is controlled first Our corporate marked of our first since
commercial technology our there adoption in remains expansion the accelerate and partner to second While improve of confident next-generation sales we we opportunities differentiated distribution in protein are our technology and pleased with direct are that quarter, network.
Customer uniquely significantly the sequencing both are globally strong. results interest team delivered of to execution our
increasing our grow, we are to solution. global and seeing continues interest funnel in sales Our
distribution about of adding personnel, and includes individuals partners.
At we sales, commercial the total our reach and the of new service second which States to end year, extend to sales continue Western support During the combination will marketing, XX the team, second Europe. of in a direct based our professionals quarter, half and United commercial direct the
have in Western growth, newly Europe. senior both to territories that Europe, positions sales added of States recently working get several the are and roles and across United United leadership States we the key We with these optimizing we a the our quarter filled resources the execution and opportunities. get hired and effective part be to continuously evaluating Western As value open and exited to targeting products.
From quickly drive improvements are Based more are sales selling training our recent our to we learnings, implementing on of management highest sales process we effective go-to-market trained at to approach. sales and standpoint, and aggressively
We are to do. initiatives, have but both making work solid we still progress on
can playbook addition we gained our to first through our we our distribution opportunity successfully to the in global team, effectively this optimistic to to the the throughout enablement giving network, that direct quarter, In are to hand, Platinum. in for confidence about XXXX. and allow access our sell they train enable ensure network network. In of time sales expand to partner grow our through the us partners we and remainder preparation partner technology expect second partner us to this partners With independently customer XXXX new distribution the we operating are
proteoforms, a for and disease-relevant disease. presentation that integrated Dr. modification artifactual she at University commercial another thought team isoform-specific help scientific to and ASMS, disease-relevant Neil of to a American generate to Kelleher's Platinum. we lab system sequencing pathology do.
In results where During University showcase major protein distinguish we was her to mass peptides team presented Gloria the Northwestern from to of spec with to work of able Dr. demonstrated members proteoforms. native Spectrometry type is mass participated not post-translational from their in identified next-generation contribute conferences spec able in that using of Dr. The analysis At Alzheimer's differentiate several the the detect Sheynkman leads. quarter, Society that the June, able Mass Platinum the Virginia from completed meeting the the Sheynkman system were second team
the generation enabled next modifications disease in the at which protein expanding at Brian proteins, discussed Reed, interrogation of personalizing Society which of Genetics role to Human Quantum-Si, Research meeting, well likely are post-translational Lastly, role primary important therapies. an as and progression play Head as sequencing, of of European Dr. the structure of direct
We driving pharma biotech, of of to Kelleher labs. base perspective, expect made that customer by market submitted the But research segment end by year.
From results presented we academic be well Sheynkman for that the are a is as parallel, our multiple as and in multiple large their see research will today our up primarily growth. protein and traction Dr. be continuing will than market Dr. important earnings publication running consumable the interest in long-term observing projects have which academic for customers were is growing typical barcoding call, so higher discussed we in These lab.
On utilization applications. we last research often locations, the
not like extremely development, existing to interest exciting for proteins, proteins the specific do area and, As drug barcodes to need characterize numbers and who of of application and expression is barcodes to a of large spec. used mass proteins for protein characteristics. high in therapeutic in using It many customers is technologies and can with today be feasible delivery challenging expensive reminder, instances, is in multiplex screening of peptide vivo. but X an of do selection streamline to of screening
Using that demonstrated successful has biological barcodes, generated of have power in minimal They in small, report required protein of they of are fraction these model vivo work excited address Platinum impact this a compared customers We of Platinum and peptide mRNAs the target. existing the their a constructs the highly the X designed that of have screen a of a cost to the to and of our demonstrates function results. address with minimal sequenceable an complex library recently problem proteomics We mouse to problem. technologies. performed biotech believe barcodes to development with on expertise in drug power
a macro confident That the longer said, drive Platinum significant differentiated believe to an be in are perspective, going from spending and and forward. historical market, point, proposition, continue averages to technology customers. adoption to value is expect quarter-over-quarter many in than with Based cycles offers we we our able Finally, in capital consistent to that cases. this upon price sales $XX,XXX value are we growth remains cautious market uniquely
roadmap. is Our on deliver priority second innovation our to
We across to our enhancements drive are instrumentation, continuing chemistry, and software.
are R&D we continues execute and seeing that Our of effort. exceptionally results well team to
coverage incorporates acid ever As evolution we are per number delivered our proteins, Version new kit peptide. this a our be peptides advancements April, The Today, a amino with that February, protein, Version in artificial in Version is sequencing roadmap. our and customers Platinum announce recognizer Version expand pleased per overall overall X to kit. next releasing sequencing reminder, we kit, in expanding increase X X to our in to And new X sequencing kit.
The intelligence. more up sample. the includes are of amino that we more further an we Software version per see sequence Analysis acids kit see of that able sequencing output the With new a will followed of chemistry and
the the the As updated the over sequencing coverage, million kit Version Analysis and Leveraging our have increase the run.
From are with per software signatures release. more more double a accuracy of a April X.X This we database improve than lowers cost part the the version predicted expanded artificial by the and the Software. kinetic amino delivers we intelligence than now Version per X.X-fold incorporated part customer metrics that a of each of more acid an of and sample as modification X database amino over of the tools April detection, software customers than in output kit. post-translational perspective, parameters database this new part X X.X-fold see Platinum release, overall as also number the will release, in releasing further output kit sequencing contains of parameters, acid
more they tell kit, story.
Compared do a more provides achieved cost those organization full improvements X customers improvement in of and technology increase year output new in the August to roadmap X.X-fold is X performance reduction a the and R&D demonstrates than has in in X.X-fold and per acid. the Version are place a This X been we not While Version kit just amino that with success. sequencing our put than in XXXX impressive,
to X innovation share Beyond to we end the we pleased that products expect are And release remains Version new by kit year. of our the launch, the X robust. pipeline
our prep kit. The product X be will Version new library first a of
of Our number goal increase continue is our types, sample to with compatibility an increasing applications. to with and technology kit proteins, the this of
being designed to product barcoding The specifically address new second is applications.
customers this a accelerate are sample we work, provide barcoding from to specific improving developing interest multiple a segments. market prior discussed their As range and prep seeing increasing application. further to sequencing, significant the are in across call, we while earlier of library dynamic customers protein kit in barcoding in time reduction also expect we that the prep To will sensitivity
pipeline prep, our to of instrumentation progress continuing library software, to innovation and are addition chemistry, sequencing we on across In roadmap. make our innovations solid
our exciting forward look some an we and that currently developments later are to have Day area about sharing We this progressing planning technology in Investor this the development at process, area for we details in that are through more year.
financial to We Our fiscal discipline. preserve laser-focused strength. third on priority remain is
Now that improvement halfway through results. can steady year, we operating see our we in are a the
committed progress, We while continuing our we and details, and efforts.
Jeff innovation are commercialization our the of efficient expenses remain year, in pleased operating with the accelerating have overall more invest meaningfully pace capital. we but reduced use provide prior of our will our to over to
will We of appropriate of a Keyes to Delivering and turn balance Platinum. two results. are foundation in our to the financial fiscal to top ramp the the striking goals over discipline call come.
I'll and innovation our Jeff confident these be that remains investing of review growth that years for up are the priority we commercial now
